Almac’s Predictive Assay for Immuno-Oncology

This gene expression based assay identifies a molecular subgroup of cancers that exhibit activation of immune checkpoint proteins such as PD-L1 and ID01, which results in immune system evasion and cancer cell survival.

Almac is developing this assay as a means of prospectively identifying patients likely to respond to PD-L1 targeted therapies.


This assay has the potential to be used as a companion diagnostic for immune checkpoint inhibitor based therapy across a range of disease areas.

Validation of the underlying biology which connects immune checkpoint activation to DNA damage has been published in the Journal of the National Cancer Institute.

Contact Us

Related resources

  • Publication

    Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

    Learn more
  • News

    Almac Group Discover an Exciting Link between its Immune Response Assay and Checkpoint Inhibitor Based Therapy

    Learn more
  • Poster

    DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer

    Learn more